Suppr超能文献

破译与类鼻疽伯克霍尔德菌和鼻疽伯克霍尔德菌脂多糖O抗原相关的最小抗原表位。

Deciphering minimal antigenic epitopes associated with Burkholderia pseudomallei and Burkholderia mallei lipopolysaccharide O-antigens.

作者信息

Tamigney Kenfack Marielle, Mazur Marcelina, Nualnoi Teerapat, Shaffer Teresa L, Ngassimou Abba, Blériot Yves, Marrot Jérôme, Marchetti Roberta, Sintiprungrat Kitisak, Chantratita Narisara, Silipo Alba, Molinaro Antonio, AuCoin David P, Burtnick Mary N, Brett Paul J, Gauthier Charles

机构信息

Institut de Chimie IC2MP, CNRS-UMR 7285, Équipe Synthèse Organique, Groupe Glycochimie, Université de Poitiers, 4, rue Michel Brunet, Poitiers, 86073, France.

Department of Chemistry, Wroclaw University of Environmental and Life Sciences, C. K. Norwida 25, Wroclaw, 50-375, Poland.

出版信息

Nat Commun. 2017 Jul 24;8(1):115. doi: 10.1038/s41467-017-00173-8.

Abstract

Burkholderia pseudomallei (Bp) and Burkholderia mallei (Bm), the etiologic agents of melioidosis and glanders, respectively, cause severe disease in both humans and animals. Studies have highlighted the importance of Bp and Bm lipopolysaccharides (LPS) as vaccine candidates. Here we describe the synthesis of seven oligosaccharides as the minimal structures featuring all of the reported acetylation/methylation patterns associated with Bp and Bm LPS O-antigens (OAgs). Our approach is based on the conversion of an L-rhamnose into a 6-deoxy-L-talose residue at a late stage of the synthetic sequence. Using biochemical and biophysical methods, we demonstrate the binding of several Bp and Bm LPS-specific monoclonal antibodies with terminal OAg residues. Mice immunized with terminal disaccharide-CRM197 constructs produced high-titer antibody responses that crossreacted with Bm-like OAgs. Collectively, these studies serve as foundation for the development of novel therapeutics, diagnostics, and vaccine candidates to combat diseases caused by Bp and Bm.Melioidosis and glanders are multifaceted infections caused by gram-negative bacteria. Here, the authors synthesize a series of oligosaccharides that mimic the lipopolysaccharides present on the pathogens' surface and use them to develop novel glycoconjugates for vaccine development.

摘要

类鼻疽杆菌(Bp)和鼻疽杆菌(Bm)分别是类鼻疽病和鼻疽病的病原体,可在人类和动物中引发严重疾病。研究强调了Bp和Bm脂多糖(LPS)作为候选疫苗的重要性。在此,我们描述了七种寡糖的合成,这些寡糖是具有与Bp和Bm LPS O抗原(OAg)相关的所有已报道乙酰化/甲基化模式的最小结构。我们的方法基于在合成序列的后期将L-鼠李糖转化为6-脱氧-L-塔罗糖残基。使用生化和生物物理方法,我们证明了几种Bp和Bm LPS特异性单克隆抗体与末端OAg残基的结合。用末端二糖-CRM197构建体免疫的小鼠产生了与Bm样OAg交叉反应的高滴度抗体反应。总体而言,这些研究为开发对抗由Bp和Bm引起的疾病的新型治疗方法、诊断方法和候选疫苗奠定了基础。类鼻疽病和鼻疽病是由革兰氏阴性细菌引起的多方面感染。在此,作者合成了一系列模拟病原体表面存在的脂多糖的寡糖,并将它们用于开发用于疫苗开发的新型糖缀合物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验